Results 41 to 50 of about 9,024 (223)

Torsadogenic risk of antipsychotics : combining adverse event reports with drug utilization data across Europe [PDF]

, 2013
Antipsychotics (APs) have been associated with risk of torsade de Pointes (TdP). This has important public health implications. Therefore, (a) we exploited the public FDA Adverse Event Reporting System (FAERS) to characterize their torsadogenic profile; (
Barbui, Corrado, Sturkenboom, Miriam, Barbui Corrado, Marija Kalaba (487415), Miriam Sturkenboom (408749), Barbui, C. (Corrado), Corrado Barbui, Kalaba M, Sturkenboom M, Fabrizio De Ponti (487418), Godman, Brian, Ariola Koci, Raschi, E. (Emanuel), Ponti, F. (Fabrizio) de, Poluzzi Elisabetta, Koci, A. (Ariola), Bjorn Wettermark, Elisabetta Poluzzi, Moretti, U. (Ugo), Miriam Sturkenboom, Godman Brian, Koci Ariola, Bennie, Marion, Brian Godman (487412), Godman B, Moretti U, Moretti Ugo, Koci, Ariola, De Ponti Fabrizio, Godman, B. (Brian), Sturkenboom Miriam, Wettermark B, Sturkenboom, M.C.J.M. (Miriam), Marija Kalaba, Emanuel Raschi (487410), Marion Bennie, Raschi Emanuel, Brian Godman, Kalaba, M. (Marija), Bennie Marion, Wettermark Bjorn, Raschi, Emanuel, Poluzzi, Elisabetta, Ugo Moretti, Elisabetta Poluzzi (487411), De Ponti, Fabrizio, Alfonso Carvajal, Marion Bennie (487416), Ugo Moretti (487414), Ariola Koci (487413), Moretti, Ugo, Wettermark, B. (Bjorn), Kalaba Marija, Poluzzi, E. (Elisabetta), Barbui C, Wettermark, Bjorn, Fabrizio De Ponti, Corrado Barbui (242747), Emanuel Raschi, Kalaba, Marija, Bennie, M. (Marion), Bennie M, Bjorn Wettermark (487417)   +62 more
core   +1 more source

Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End‐Stage Kidney Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background The rate of sudden cardiac death in the hemodialysis population exceeds that of the general population by >20‐fold. Hemodialysis patients may be particularly susceptible to sudden cardiac death provoked by drug‐induced QT prolongation because ...
Magdalene M. Assimon, Lily Wang, Patrick H. Pun, Wolfgang C. Winkelmayer, Jennifer E. Flythe   +4 more
doaj   +1 more source

Acquired Long QT Syndrome and Torsade de Pointes Associated with HIV Infection

Case Reports in Medicine, 2010
Here, we report the case of an HIV infected patient that was treated for pneumonia with a macrolid antibiotic. The patient experienced a prolongation of the already pathologic QTc interval resulting in repeated torsades de pointes necessitating CPR and ...
Alexander Shimabukuro-Vornhagen, Jan Rybniker, Shahram Zoghi, Gerd Faetkenheuer, Guido Michels, Erland Erdmann, Michael von Bergwelt-Baildon, Matthias Kochanek   +7 more
doaj   +1 more source

Torsade de pointes [PDF]

Clinical Cardiology, 1993
AbstractThe polymorphic ventricular tachycardia torsade de pointes can occur in the congenital long QT syndromes or as a consequence of therapy with QT‐prolonging drugs. The latter can include not only antiarrhythmic drugs such as quinidine, but also a number of drugs which are not usually considered to have major cardiovascular effects: these include ...
openaire   +2 more sources

Ondansetron induced torsades de pointes

Clinical Case Reports, 2019
A single dose of oral Ondansetron can precipitate torsades de pointes and other arrhythmias in patients with risk factors that may prolong QTc interval.
Eshan Patel, Danielle Rosemond, Ashwad Afzal   +2 more
doaj   +1 more source

Severe hypomagnesemia with secondary hypocalcaemia (HSH) presenting as recurrent self terminating Torsades de pointes

IHJ Cardiovascular Case Reports, 2020
Torsades de Pointes (TdP) is a potentially fatal cardiac arrhythmia, defined as the combination of polymorphic ventricular tachycardia with prolonged QT-interval. Hypomagnesemia of any cause can predispose to TdP.
Manjappa Mahadevappa, MD, DM,, Prashanth Kulkarni, MD, DM,, Pushpa NB, MBBS, MD,, Poornima KS, MBBS, PGDCC,   +3 more
doaj   +1 more source

A Novel Frameshift Mutation, KCNH2 [p.Asp896ArgfsX79], Leading to Malignant Ventricular Arrhythmia, Identified After Treatment of Gastrointestinal BleedingNovel Teaching Points

CJC Open, 2021
A novel frameshift mutation in the KCNH2 gene for long QT syndrome type 2 (LQTS2) was identified after torsades des pointes ventricular tachycardia in a 49-year-old patient managed with octreotide and nadolol for an acute variceal bleed.
Wan Cheol Kim, MD, FRCPC, Edmond Lemire, MD, PhD, FRCPC, FCCMG, Siddarth Nosib, BSc, Shravankumar Nosib, MD, FRCPC   +3 more
doaj   +1 more source

Contraindicated drug–drug interactions and associated adverse drug reactions in an observational cohort study of 4543 paediatric hospitalized patients

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval, Sylvain Goutelle, Inesse Boussaha, Xavier Dode, Yanis Mimouni, Kim An Nguyen, Behrouz Kassai   +6 more
wiley   +1 more source

Drug-Induced QT Prolongation as a Result of an Escitalopram Overdose in a Patient with Previously Undiagnosed Congenital Long QT Syndrome

Case Reports in Medicine, 2014
We present a case of drug-induced QT prolongation caused by an escitalopram overdose in a patient with previously undiagnosed congenital LQTS. A 15-year-old Caucasian female presented following a suicide attempt via an escitalopram overdose.
Paul Singh, J. Martin Maldonado-Duran
doaj   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

Clinical Pharmacology &Therapeutics, EarlyView.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore, Melissa S. Bourque, Andreas Halman, José A. G. Agúndez, Cynthia A. Prows, Keiko Hikino, Matthias Schwab, Carolyn J. Oxencis, Dharmisha Chauhan, Meta H.M. Diekstra, Susie E. Long, Gillian C. Bell, Andrea Gaedigk, Michelle Whirl‐Carrillo, Teri E. Klein, Kelly E. Caudle, Rachel Conyers   +16 more
wiley   +1 more source